Showing results (11-20 of 73) with videos related to
Sort By:
Pageof 8
Clinical Pharmacokinetics|March 29, 2017
Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal ImpairmentThomas C Marbury, Anne Flint, Jacob B Jacobsen, et al.Drug Design, Development and Therapy|August 31, 2016
Pharmacokinetic profile of defibrotide in patients with renal impairmentPaola Tocchetti, Elena Tudone, Jean-Francois Marier, et al.Neurology(R) Neuroimmunology & Neuroinflammation|September 29, 2017
Impact of siponimod on vaccination response in a randomized, placebo-controlled studyMike Ufer, Kasra Shakeri-Nejad, Anne Gardin, et al.International Journal of Clinical Pharmacology and Therapeutics|August 27, 2015
Pharmacokinetic and pharmacodynamic interaction of siponimod (BAF312) and propranolol in healthy subjectsShibadas Biswal, Florine Polus, Parsar Pal, et al.Investigational New Drugs|March 20, 2021
Effect of severe renal impairment on the pharmacokinetics of brigatinibNeeraj Gupta, Michael J Hanley, David Kerstein, et al.Clinical Pharmacology in Drug Development|January 15, 2021
Pharmacokinetics of Gepotidacin in Subjects With Normal Hepatic Function and Hepatic ImpairmentMohammad Hossain, Courtney Tiffany, Yu Tao, et al.Cancer Chemotherapy and Pharmacology|June 18, 2014
Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjectsNarayana I Narasimhan, David J Dorer, Jeffrey Davis, et al.Journal of Clinical Pharmacology|January 12, 2019
Characterization of the Effect of Renal Impairment on Upadacitinib PharmacokineticsMohamed-Eslam F Mohamed, Sheryl Trueman, Tian Feng, et al.Investigational New Drugs|April 13, 2023
Brigatinib pharmacokinetics in patients with chronic hepatic impairmentMichael J Hanley, David Kerstein, Meera Tugnait, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 24, 2004
Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once dailyRobert Z Harris, Desmond Padhi, Thomas C Marbury, et al.Pageof 8